Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.31 |
| ▸ | PDXK | O00764 | 1/20 | 0.31 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.31 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14291679 | 0.78 | DHFR (0.37) | — | |
| SCHEMBL15942981 | 0.77 | ALDH1A1 (0.33) | KDM4ECSNK1A1CLK4PDXKTYRO3 | |
| SCHEMBL27809349 | 0.77 | ALDH1A1 (0.33) | KDM4ECSNK1A1CLK4PDXKTYRO3 | |
| SCHEMBL4579208 | 0.77 | NOS3 (0.36) | KDM4ECSNK1A1CLK4PDXKTYRO3 | |
| SCHEMBL30238970 | 0.77 | NOS3 (0.36) | KDM4ECSNK1A1CLK4PDXKTYRO3 | |
| SCHEMBL7966254 | 0.77 | KDM4E (0.32) | KDM4ECSNK1A1CLK4PDXKTYRO3 | |
| SCHEMBL16580713 | 0.77 | PDXK (0.48) | KDM4ECSNK1A1CLK4PDXKTYRO3 | |
| SCHEMBL27149700 | 0.77 | GABRA1 (0.36) | KDM4ECSNK1A1CLK4PDXKTYRO3 | |
| SCHEMBL1917353 | 0.77 | CSNK1A1 (0.35) | KDM4ECSNK1A1CLK4PDXKTYRO3 | |
| SCHEMBL6203110 | 0.76 | KDM4E (0.31) | KDM4ECSNK1A1CLK4PDXK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016001077-A1 | COMPOUNDS INHIBITING THE ENZYME MONOPOLAR SPINDLE 1 KINASE,PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | IEO - ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2016-01-07 | — | — | WO | claimed |
| US-20260078126-A1 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4051677-B1 | BICYCLIC NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF SALT-INDUCED KINASE SIK2 | CANCER RESEARCH TECH LTD (GB) | 2026-03-18 | — | — | EP | disclosed |
| US-12509457-B2 | Bicyclic nitrogen containing heterocycles as inhibitors of salt-induced kinase SIK2 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-12-30 | — | — | US | disclosed |
| US-12398145-B2 | Bicyclic urea kinase inhibitors and uses thereof | THE BROAD INSTITUTE, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| CN-113747894-B | Degradation agents for fibroblast growth factor receptor 2 (FGFR 2) | 丹娜-法伯癌症研究公司 | 2025-05-16 | — | — | CN | disclosed |
| US-12121521-B2 | Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis | THE GENERAL HOSPITAL CORPORATION (US) | 2024-10-22 | — | — | US | disclosed |
| US-20240245695-A1 | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2024-07-25 | — | — | US | disclosed |
| WO-2024125451-A1 | PIPERINDIN-ONES DERIVATIVES, PREPARATION METHODS AND MEDICINAL USES THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-06-20 | — | — | WO | disclosed |
| CN-117986272-A | Condensed polycyclic compounds, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
| US-7084270-B2 | Pyrimido compounds having antiproliferative activity | HOFFMAN-LA ROCHE INC. (US) | 2006-08-01 | — | — | US | disclosed |
| EP-1615928-A1 | PYRIMIDO COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-01-18 | — | — | EP | disclosed |
| EP-1581531-A1 | PYRIDINO[2,3-D]PYRIMIDINE DERIVATIVES AS SELECTIIVE KDR AND FGFR INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2005-10-05 | — | — | EP | disclosed |
| EP-1556384-A2 | PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004089955-A1 | PYRIMIDO COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-10-21 | — | — | WO | disclosed |
| US-20040204427-A1 | Pyrimido compounds having antiproliferative activity | CHEN YI (US) | 2004-10-14 | — | — | US | disclosed |
| WO-2004056822-A1 | PYRIDINO `2, 3-D! PYRIMIDINE DERIVATIVES AS SELECTIVE KDR AND FGFR INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-08 | — | — | WO | disclosed |
| US-20040122029-A1 | Novel dihydropyridinone compounds | LIU JIN-JUN (US) | 2004-06-24 | — | — | US | disclosed |
| WO-2004018472-A2 | PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-04 | — | — | WO | disclosed |
| US-20040038995-A1 | Pyrimido compounds having antiproliferative activity | CHEN YI (US) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12121521-B2 | Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis | SOST, CSF1R, SIK2 | KDM4E 1918/4885CSNK1A1 116/4885CLK4 421/4885 |
| US-20260078126-A1 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | SIK2, SBK3, SIK3 | KDM4E 4485/4885CSNK1A1 19/4885CLK4 77/4885 |
| US-12398145-B2 | Bicyclic urea kinase inhibitors and uses thereof | SIK1, SIK2, SIK3 | KDM4E 3066/4885CSNK1A1 190/4885CLK4 45/4885 |
| US-20040204427-A1 | Pyrimido compounds having antiproliferative activity | FGFR3, FGFR1, FGFR4 | KDM4E 2122/4885CSNK1A1 1111/4885CLK4 2151/4885 |
| US-12509457-B2 | Bicyclic nitrogen containing heterocycles as inhibitors of salt-induced kinase SIK2 | SIK2, SIK1, SIK3 | KDM4E 1337/4885CSNK1A1 99/4885CLK4 33/4885 |
| US-20040122029-A1 | Novel dihydropyridinone compounds | FGFR1, FGFR3, FGFR4 | KDM4E 743/4885CSNK1A1 576/4885CLK4 1362/4885 |
| US-20240245695-A1 | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS | SIK2, SIK1, SIK3 | KDM4E 1681/4885CSNK1A1 164/4885CLK4 115/4885 |
| US-20040038995-A1 | Pyrimido compounds having antiproliferative activity | LCK, FGFR1, FGFR3 | KDM4E 1030/4885CSNK1A1 639/4885CLK4 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.